Extended Longevity
IRB 2021-2023.
The Longevinaut Study #1
THE SAFETY AND EFFECTIVENESS OF THE EXTENDED LONGEVITY
PROTOCOL ON THE EPIGENETIC AGING RATE IN HEALTHY INDIVIDUALS
Protocol Number: TD-EL-001
IRB approval number: IRCM-2019-285
Click here for Study
Conducted by
Quantum Functional Medicine of Carlsbad, California
Dr. Juergen Winkler, MD
Through the Institute of Regenerative and Cellular Medicine (IRCM) of Santa Monica,
California, Executive Director Dr. Barbara Krutchkoff, PhD
An Institutional Review Board (IRB) has been conducted by Dr. Juergen Winkler of Quantum Functional
Medicine of Carlsbad, California, under the auspices of the Institute of Regenerative and Cellular
Medicine (IRCM) of Santa Monica, California, sponsored by Extended Longevity, Inc. of Kula, Hawaii,
in support of the Extended Longevity Protocol in a study to demonstrate the reversal of three primary
biomarkers measuring the ten (10) determinant factors of aging.
The final report for Longevinaut Study #1 includes a cohort of 11 men and women ages 55–75 who have
taken the Extended Longevity Protocol daily for up to one year.
